The FDA approved the Alzheimer’s drug Leqembi from Eisai and Biogen


Biogen (BIIB) Gets a Buy from Needham

In a report released today, Ami Fadia from Needham maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of $300.00. The company’s shares closed today at $279.25.Fadia covers the Healthcare sector…


This article was originally published by Read the original article here.

Previous article: Dow gains 700 points as stocks log biggest advance in 5 weeks
Next articleThe Moneyist: ‘We can only afford a fraction of a second home’: I want to pool money with my wife’s siblings to buy a home close to our in-laws. How do I delicately broach the subject?


Please enter your comment!
Please enter your name here